Metabolic complications of antiretroviral therapy in HIV-infected children

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 1, 2008, Pages 37-49

  Eley, Brian ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antiretroviral therapy; Children; Dyslipidaemia; Hyperlactataemia; Insulin resistance; Lipodystrophy; Metabolic complications; Mitochondrial toxicity

Indexed keywords

ABACAVIR; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ASCORBIC ACID; BEZAFIBRATE; BICARBONATE; DIDANOSINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TENOFOVIR; THIAMINE; UBIDECARENONE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; BODY FAT DISTRIBUTION; BONE DENSITY; BONE MINERAL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MALAISE; MEDICAL RESEARCH; METABOLIC BONE DISEASE; METABOLIC DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE CRAMP; MYOPATHY; NEPHROTOXICITY; NEUROLOGIC DISEASE; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PRENATAL DRUG EXPOSURE; PREVALENCE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SEIZURE; SIDE EFFECT;

ADIPOSITY; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; CHILD; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LACTASE; LIPID METABOLISM DISORDERS; METABOLIC DISEASES; MITOCHONDRIAL DISEASES;

EID: 39049161921     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.1.37     Document Type: Review

References (97)

1. Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J Med 2003;349:2283-5
2. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003;9:867-73
3. Brogly S, Williams P, Saege GR, et al. Antiretroviral treatment in paediatric HIV infection in the United States: from clinical trials to clinical practice. J Am Med Assoc 2005;293:2213-20
4. UNICEF: Joint press release: Access to HIV therapy grew significantly in 2006, but significant obstacles remain to approaching universal access to HIV services. Available at: URL: www.unicef.org/media/ media_39392.html?q=printme [Accessed December 2007]
5. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Inf 2001;77:158-73
6. Kukuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708
7. Brinkman K, Ter Hofstede HJM, Burger DM, Sneitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44
8. Day L, Shijuma C, Gerschenson M. Mitochondrion. 2004;4:95-109
9. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol γ hypothesis. AIDS 2006;20:675-84
10. Noguera A, Fortuny C, Muñoz-almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114:598-603
11. Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 Study. Abidjan, Ivory Coast Pediatr 2006;118:e1071-e1077
12. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-85
13. Cooper ER, Dimauro S, Sullivan M, et al. Biopsy-confirmed mitochondrial dysfunction in an HW-exposed infant whose mother received combination antiretrovirals during the last 4 weeks of pregnancy. XV International Conference on AIDS, Bangkok (July 2004) [abstract TUPEB4394]
14. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007;21:929-38
15. Tovo P-A, Chiapello N, Gabiano C, Zaviani M, Spada M. Zidovudine administration during pregnancy and mitochondrial disease in the offspring. Antiviral Ther 2005;10:697-9
16. Godfried M, Boer K, Beuger S, Scherpbier H, Kuijpers T. A neonate with macrosomia, cardiomyopathy and hepatomegaly born to an HIV-infected mother. Eur J Pediatr 2005;164:190-2
17. Elenga N, Msellati P, Fassinou P, Viho I, Dabis E. Zidovudine-associated mitochondriopathy: three possible observations in Abidjan, Cote d'Iviore. Bull Soc Pathol Exot 2004;97:253-6
18. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in the United States cohorts. J Acquir Immun Defic Syndr 2000;25:261-8
19. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003;17:1565-8
20. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactataemia in human immunodeficiency virus-infected children receiving antiretroviral therapy. Pediatr Infect Dis J 2003;22:778-82
21. Mccomsey GA, Yau L. Asymptomatic hyperlactataemia: predictive value, natural history and correlates. Antivir Ther 2004;9:205-12
22. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007;45:254-60
23. Imhof A, Ledergerber B, Günthard HF, Haupts S, Weber R, and the Swiss HIV cohort study. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin Infect Dis 2005;41:721-8
24. Rey C, Prieto S, Medina A, Pérez C, Concha A, Menéndez S. Fatal lactic acidosis during antiretroviral therapy. Pediatr Crit Care Med 2003;4:485-7
25. Church JA, Mitchell WG, Gonzalez-gomez I, et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. Pediatrics 2001;138:748-51
26. Carter RW, Singh J, Archambault C, Arrieta A. Severe lactic acidosis in association with reverse transcriptase inhibitors with potential response to L-carnitine in a pediatric HIV-positive patient. AIDS Patient Care STDs 2004;18:131-4
27. Geddes R, Knight S, Moosa MYS, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006;96:722-4
28. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS Society - USA Panel. J Acquir Immune Defic Syndr 2002;31:257-75
29. Longeran JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003;17:2495-9
30. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005;112:103-9
31. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002;110:e56
32. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-51
33. Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral regimens. Pediatrics 2004;114:e235-42
34. Rhoads MP, Smith CJ, Tudor-williams G, et al. Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Med 2006;7:16-24
35. Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 2005;88:956-66
36. Santos FS, Rangel LGG, Saucedo GP, Rosales GV, Novales MGM. Hypertriglyceridemia and hypercholesterolemia inhuman immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res 2006;37:129-32
37. Farley J, Gona P, Crain M, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 2005;38:480-7
38. Carter RJ, Wiener J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006;41:453-60
39. Lang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-31
40. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/ low HDL levels in treated HIV patients. AIDS 2001;15:2397-406
41. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17:S141-8
42. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: Pathogenesis and cardiovascular risk. Am J Ther 2006;13:248-60
43. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004;18:1037-41
44. Mccomsey GA, O'Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007;21:921-7
45. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27
46. Dubé MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidemia in patients with HIV infection: AIDS Clinical trials Group study A5148. Antivir Ther 2006;11:1081-9
47. Norméin L, Yip B, Montaner J, et al. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Med 2007;8:346-56
48. Bennett MT, Johns KW, Bondy GP. Ezetimbe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis 2007;6:15
49. Cannon C, Braunwald E, Mccrabe C, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
50. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphological changes. AIDS Rev 2006;8:191-203
51. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for proteasae inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005;19:1051-8
52. Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful HAART to TRIZIVIR (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86
53. Möbius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174-80
54. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results from a randomized study. J Acquir Immune Defic Syndr 2007;44:139-47
55. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoathropy. AIDS 2006;20:2043-50
56. American Academy of Pediatrics: Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998;101:141-7
57. Kavey RW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Casdiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-38
58. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007;27:1803-10
59. Garosi G, Quiros-Roldan E, Torti C, et al. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). Infect 2007;35:134-42
60. McComsey G, Bhumbra N, Ma J, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics 2003;111:e275-e281
61. Ellis KJ, Shypailo RJ, Pratt JA, Pond WG: Accuracy of dual-energy x-ray absorptiometry for body-composition measurements in children. Am J Clin Nutr 1994;60:660-5
62. Bramilla P, Manzoni P, Sironi S, et al. Peripheral and abdominal adiposity in childhood obesity. Int J Obes Relat Metab Disord 1994;18:795-800
63. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract 2007;61:999-1014
64. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-8
65. Brambilla P, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in the absence of lipodystrophy. AIDS 2001;15:2415-22
66. Viganòa, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003;32:482-9
67. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005;40:161-8
68. Torres AMS, Muniz RM, Madero R, Borque C, Garcia-Miguel MJ, Gómez MIDJ. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005;164:271-6
69. Hartman K, Verweel G, De Groot R, Hartwig NG. Detection of lipodystrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:427-31
70. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004;18:1753-68
71. Paediatric European Network for Treatment of AIDS (Penta). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002;359:733-40
72. Tebas P, Zhang J, Yarasheski K, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. J Acquir Immune Defic Syndr 2007;45:193-200
73. Viganò A, Brambilla P, Cafarelli L, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from a protease inhibitor to efavirenz. Antivir Ther 2007;12:397-302.
74. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007;195:1754-61
75. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinaemia and elevated waist/hip ratio. AIDS 2007;21:47-57
76. Sutinen J, Walker UA, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007;12:97-105
77. Mallon PWG, Millar J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in men - a randomized, placebo-controlled study. AIDS 2006;20:1003-10
78. Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005;18:25-33
79. Roubernoff R, Weiss L, Mcdermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999;13:1373-5
80. Driscoll SD, Meininger GE, Ljungquist K, et al. Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2004;89:2171-8
81. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. Acquir Immune Defic Syndr 2007;45:286-97
82. Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity, J Clin Endocrinol Metab 2007;92:1049-57
83. Hultman SC, Mcphil LE, Donaldson JH, Wohl DA. Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plast Surg 2007;58:255-63
84. Aboud M, Elgalib A, Kulasegarem R, Peters B. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007;61:463-72
85. Bitnum A, Sochett E, Dick PT, et al. Insulin sensitivity and β-cell function in protease inhibitor-treated and -naïve human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005;90:168-74
86. Nolan D, Hammond E, James I, Mckinnon E. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003;8:617-26
87. Beregszàszi M, Jaquet D, Lévine M, et al. Severe insulin resistance contrasting with mild anthropometric changes in the adipose tissue of HIV-infected children with lipohypertrophy. Int J Obes 2003;27:25-30
88. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naïve HIV-infected children. AIDS 2003;17:1319-27
89. Gaughan DM, Mofensonlm, Hughes MD, Seage GR III, Ciupak GL, Oleske JM. Osteonecrosis of the hip (Legg-Calvé-Perthes Disease) in human immunodeficiency virus-infected children. Pediatrics 2002;109:e74
90. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7
91. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. J Am Med Assoc 2004;292:191-201
92. Mora S, Sala N, Bricalli D, Zuin G, Chimuello G, Viganò A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001;15:1823-9
93. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004;89:24-8
94. Jacobson DL, Spiegelman D, Duggan C, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr 2005;41:339-46
95. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumerate and an optimised background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006;118:711-18
96. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006;42:108-14
97. Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database of Systematic Reviews, 2007;(2):CD005645